Ipamorelin

Ipamorelin is a highly selective GHRP with minimal side effects compared to earlier growth hormone secretagogues. It boosts natural GH secretion while avoiding significant stimulation of cortisol or prolactin. It has been investigated in both in vitro models and animal research for anti-aging, muscle recovery, and fat-loss protocols.

• Selective GHRP receptor agonist
• Stimulates endogenous GH secretion via ghrelin-mimetic action
• Low activity on ACTH, cortisol, and prolactin secretion

• unit: mcg

  low dose: 100

  frequency: 1-3 times daily (typically at bedtime)

  high dose: 300

  standard dose: 200

  administration route: Subcutaneous (SQ)

• 200 mcg nightly (5 nights on, 2 nights off) or 200–300 mcg up to 3x/day. Limit use to 8-week cycles followed by equal off time to maintain pituitary sensitivity.

common: ["Mild nausea, especially first week","Headaches, lightheadedness","Water retention and bloating (dose-dependent)","Increased appetite"]

long term: ["Potential insulin resistance with heavy prolonged use"]

sequence: Aib-His-2-methyl-L-tyrosine-D-lysino-D-alaninamide

half life: Approximately 2 hours

degradation: Metabolized hepatically and cleared renally

molecular weight: 711.86

molecular formula: C38H49N9O5

tissue specificity: Affects GH-receptor expressing tissues like muscle, adipose, and connective tissue

• Ipamorelin, the first selective growth hormone secretagogue.mechanismPMID 9849822 ↗
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers.clinicalPMID 10496658 ↗
• Ipamorelin induces longitudinal bone growth in rats.preclinicalPMID 10373343 ↗